|
|
Drugs for Ewing's Family of Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 302)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Dolutegravir | approved | Phase 4 | 150 | 1051375-16-6 | 54726191 | | 2 | | Darunavir | approved | Phase 4 | 210 | 635728-49-3, 206361-99-1 | 213039 | (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE (3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate (3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate (3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate (3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate 206361-99-1 2f80 2f81 2f8g 2hs1 2hs2 2idw 2ien 3bvb 3cyw 3d1z 3d20 618109-00-5 AC1L4U4V AIDS073035 CHEBI:367163 CHEMBL1323 | CID213039 Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester D03656 DB01264 Darunavir Darunavir (USAN/INN) Darunavir [USAN] Darunavirum Darunavirum [INN-Latin] Darunavirum [INN-latin] LS-187026 LS-187772 LS-191295 MolPort-003-846-141 N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide Prezista Prezista(TM) TMC 114 TMC-114 TMC114 UIC 94017 UIC-94017 UIC-96017 UNII-YO603Y8113 [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester {(1S,2R)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester | |
| | 3 | | Ritonavir | approved, investigational | Phase 4 | 883 | 155213-67-5 | 392622 | 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate 155213-67-5 1hxw 1sh9 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate 538, ABT A-84538 ABBOTT-84538 ABT 538 ABT 84538 ABT-538 ABT538 AC-733 AC1L94GB AKOS000280930 Abbott 84538 BIDD:GT0387 BIDD:PXR0023 Bio-0093 C07240 C37H48N6O5S2 CHEBI:45409 CHEMBL163 CID392622 CPD000466395 D00427 D019438 | DB00503 DRG-0244 FT-0082824 HMS2051B08 HSDB 7160 LS-148860 MLS000759541 MLS001424063 MolPort-000-883-877 N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide NCGC00159462-02 NSC693184 Norvir Norvir (TM) Norvir (TN) Norvir Sec RIT RTV Ritonavir Ritonavir (JAN/USAN/INN) Ritonavir [USAN] Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavirum S1185_Selleck SAM001246783 SMR000466395 STK634209 ZINC03944422 ritonavir | |
| | 4 | | Anti-Retroviral Agents | | Phase 4, Phase 2, Phase 1 | 3296 | | | | 5 | | Anti-HIV Agents | | Phase 4, Phase 2, Phase 1 | 3162 | | | | 6 | | Antiviral Agents | | Phase 4, Phase 2, Phase 1 | 9967 | | | | 7 | | Anti-Infective Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 22062 | | | | 8 | | protease inhibitors | | Phase 4, Phase 2 | 5471 | | | | | 9 | | HIV Protease Inhibitors | | Phase 4, Phase 2 | 5470 | | | | 10 | | Integrase Inhibitors | | Phase 4 | 418 | | | | 11 | | HIV Integrase Inhibitors | | Phase 4 | 397 | | | | 12 | | Cytochrome P-450 CYP3A Inhibitors | | Phase 4 | 1715 | | | | 13 | | Cytochrome P-450 Enzyme Inhibitors | | Phase 4 | 3917 | | | | 14 | | Cyclophosphamide | approved, investigational | Phase 3, Phase 1, Phase 2 | 2935 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 15 | | Melphalan | approved | Phase 3, Phase 2, Phase 1 | 729 | 148-82-3 | 4053, 460612 | (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid 148-82-3 3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine 3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3025 C.B. 3025 c.b 3223-07-2 4-(Bis(2-chloroethyl)amino)-L-phenylalanine 4-14-00-01689 (Beilstein Handbook Reference) 4-[Bis(2-chloroethyl)amino]-L-phenylalanine 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine AC1LA2OE ALKERAN (TN) AY3360000 Alanine Nitrogen Mustard Alkeran AmbotzHAA1563 At-290 BIDD:GT0044 BRD-K87827419-001-02-8 BRN 2816456 BSPBio_002407 C13H18Cl2N2O2 CB 3025 CB-3025 CCRIS 374 CHEBI:165415 CHEBI:28876 CHEMBL852 CID460612 D00369 DivK1c_000653 EINECS 205-726-3 HMS2090B09 HMS2091B16 HMS502A15 HSDB 3234 IDI1_000653 KBio1_000653 KBio2_000877 KBio2_003445 KBio2_006013 KBio3_001627 KBioGR_001284 KBioSS_000877 L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine L-PAM L-Phenylalanine mustard L-Sarcolysin L-Sarcolysine L-Sarkolysin LS-15868 LS-865 | Levofalan Levofolan Levopholan M2011_SIGMA MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)) MLS001333666 MLS002153368 Melfalan Melfalano Melfalano [INN-Spanish] Melphalan (JP15/USP/INN) Melphalan [USAN:INN:BAN:JAN] Melphalanum Melphalanum [INN-Latin] Mephalan MolPort-003-665-535 NCGC00090757-01 NCGC00090757-02 NCGC00090757-03 NCI-C04853 NINDS_000653 NIOSH/AY3360000 NSC 241286 NSC 8806 NSC-8806 NSC241286 NSC8806 P-Di-(2-chloroethyl)amino-L-phenylalanine P-L-Sarcolysin P-N-Bis(2-chloroethyl)amino-L-phenylalanine Phenylalanine mustard Phenylalanine nitrogen mustard Prestwick_1006 RCRA waste no. U150 Rcra waste number U150 SK-15673 SMP2_000174 SMR000058720 SPBio_000287 SPECTRUM1500382 Sarcolysine Sarkolysin Spectrum2_000074 Spectrum3_000684 Spectrum4_000882 Spectrum5_001601 Spectrum_000397 TL8001065 TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN) TRANSGENIC MODEL EVALUATION (MELPHALAN) UNII-Q41OR9510P melphalan p-Bis(beta-chloroethyl)aminophenylalanine p-Di-(2-chloroethyl)amino-L-phenylalanine p-L-Sarcolysin p-L-sarcolysine p-N,N-bis(2-chloroethyl)amino-L-phenylalanine p-N-Bis(2-chloroethyl)amino-L-phenylalanine p-N-Di(chloroethyl)aminophenylalanine p-N-di(chloroethyl)aminophenylala nine phenylalanine nitrogen mu stard |
| | 16 | | Dactinomycin | approved | Phase 3, Phase 2 | 48 | 50-76-0 | 2019, 457193 | (- )-actinomycin d (-)-actinomycin d -pentone 01815_FLUKA 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 50-76-0 A1410_SIGMA A4262_SIGMA A9415_SIGMA AC1L1CQX AC1L9W52 ACT ACT D ACTINOMYCIN D ACTINOMYCIN D AMP ACTINOMYCIN-D ACTO-D ACon0_000471 ACon1_001004 AD AD (VAN) AI3-26374 ActD Actactinomycin A IV Actactinomycin a Iv Actinomycin 11 Cosmegen Actinomycin 11 cosmegen Actinomycin 7 Actinomycin A IV Actinomycin Aiv Actinomycin C (sub1) Actinomycin C(sub1) Actinomycin C1 Actinomycin D Actinomycin D (JP15) Actinomycin D deriv. of 3H-phenoxaocardazine Actinomycin D, sodium deoxyribonucleic acid complex Actinomycin I Actinomycin I (sub1) Actinomycin I(sub 1) Actinomycin I(sub1) Actinomycin I1 Actinomycin IV Actinomycin Iv Actinomycin X 1 Actinomycin X1 Actinomycin iv Actinomycin-(threo-val-pro-sar-meval) Actinomycin-?IV Actinomycin-[threo-val-pro-sar-meval] Actinomycindioic D Acid, Dilactone Actinomycindioic D acid, dilactone Acto-D Antibiotic From Streptomyces Parvullus Antibiotic from Streptomyces parvullus BCBcMAP01_000155 BRD-A42383464-001-02-2 Bio1_000342 Bio1_000831 Bio1_001320 C06770 C1 C62H86N12O16 CBiol_002056 CCRIS 9 CHEBI:123721 CHEBI:27666 CHEMBL1554 CHEMBL427947 CID2019 | CID457193 COSMEGEN (TN) CPD000469227 Chounghwamycin B Cosmegen D Actinomycin D00214 DACTINOMYCIN DB00970 DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA Dactinomicina Dactinomicina [INN-Spanish] Dactinomycin Dactinomycin (USP) Dactinomycin D Dactinomycin [USAN:BAN] Dactinomycine Dactinomycine [INN-French] Dactinomycinum Dactinomycinum [INN-Latin] Dilactone Actinomycin D Acid Dilactone Actinomycindioic D Acid Dilactone actin omycindioic D acid Dilactone actinomycin D acid Dilactone actinomycindioic D acid EINECS 200-063-6 FT-0080366 GNF-PF-1977 HBF 386 HBF 386 Meractinomycin HBF 386 meractinomycin HMS2052O17 HSDB 3220 LMPK14000005 LS-142 Lyovac Cosmegen Lyovac cosmegen MEGxm0_000350 MLS001424196 Meractinomycin MolPort-001-739-741 MolPort-003-925-177 NCGC00025059-02 NCGC00090796-01 NCGC00161622-01 NCGC00161622-02 NCGC00169767-01 NCI-C04682 NCI60_030539 NP-005932 NSC 3053 NSC-3053 NSC191297 NSC3053 Neuro_000003 Oncostatin K Oxamide PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA SAM001246846 SMP1_000005 SMR000469227 UNII-1CC1JFE158 UPCMLD-DP055 UPCMLD-DP055:001 UPCMLD-DP055:002 WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1 X 97 actd actinomycin D actinomycin cl actinomycin x i actinomyein-theo-val-pro-sar-meval dactinomyein d o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine |
| | 17 | | Ifosfamide | approved | Phase 3, Phase 2, Phase 1 | 400 | 3778-73-2 | 3690 | (+-)-Ifosfamid (+-)-Ifosphamide (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide (D,L)-Ifosfamide (R,S)-Ifosphamide (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI) 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 3,} 2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 36341-88-5 3778-73-2 84711-20-6 A 4942 AB00513932 AC-2113 AC1L1GHW ASTA Z 4942 Ambap3778-73-2 Asta Z 4942 BPBio1_000865 BRN 0611835 BSPBio_000785 C07047 CAS-3778-73-2 CCRIS 352 CHEBI:5864 CHEMBL1024 CID3690 Cyfos D00343 D007069 DB01181 EINECS 223-237-3 HMS1570H07 HMS2090M12 HMS2093N07 HSDB 7023 Holoxan Holoxan 1000 I-Phosphamide I06-0494 IFEX (TN) Ifex Ifosfamid Ifosfamida Ifosfamida [INN-Spanish] Ifosfamide (JAN/USP/INN) | Ifosfamide Sterile Ifosfamide [USAN:INN:BAN:JAN] Ifosfamidum Ifosfamidum [INN-Latin] Ifosphamide Ifsofamide Iphosphamid Iphosphamid(e) Iphosphamide Iso Endoxan Iso-Endoxan Isoendoxan Isofosfamide Isophosphamide Isosfamide LS-102 LS-99799 MJF 9325 MJF-9325 MLS002154021 Mitoxana Mitoxana, Ifex, Ifosfamide MolPort-003-666-704 N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German] N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine NCGC00016639-01 NCGC00179435-01 NCI-C01638 NCI60_000233 NPFAPI-04 NSC 109,724 NSC 109724 NSC-109,724 NSC-109724 NSC109,724 NSC109724 Naxamide Prestwick0_000833 Prestwick1_000833 Prestwick2_000833 Prestwick3_000833 S1302_Selleck SMR001233348 SPBio_002706 STL058690 UNII-UM20QQM95Y WLN: T6NPOTJ AM2G BO B2G Z 4942 Z-4942 Z4942 ifosfamide isosfamide {3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1, | |
| | 18 | | Doxorubicin | approved, investigational | Phase 3, Phase 2, Phase 1 | 1751 | 23214-92-8 | 31703 | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione 111266-55-8 14-Hydroxydaunomycin 14-Hydroxydaunorubicine 14-hydroxydaunomycin 14-hydroxydaunorubicine 23214-92-8 23257-17-2 24385-08-8 25311-50-6 25316-40-9 25316-40-9 (hydrochloride) 29042-30-6 AC1L1M5T AC1Q29OJ ADM ADR Adriablastin Adriacin (hydrochloride salt) Adriamycin Adriamycin PFS Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriamycin Semiquinone Adriamycin semiquinone Adriblas tina Adriblastin Adriblastina Adriblastina (TN) Adriblastina (hydrochloride salt) Aerosolized Doxorubicin BPBio1_000502 BRD-K92093830-003-04-3 BSPBio_000456 BSPBio_001031 C01661 C27H29NO11 CCRIS 739 CHEBI:28748 CHEMBL179 CID31703 Caelyx Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74 Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120 D03899 DB00997 DM2 DOX-SL Doxil Doxo Doxorubicin Doxorubicin (USAN/INN) Doxorubicin HCl | Doxorubicin Hydrochloride Doxorubicin [USAN:INN:BAN] Doxorubicin citrate Doxorubicin hydrochloride (hydrochloride salt) Doxorubicin-P4/D10 Doxorubicin-P4/D10 conjugate Doxorubicin-hLL1 Doxorubicin-hLL1 conjugate Doxorubicina Doxorubicina [INN-Spanish] Doxorubicine Doxorubicine [INN-French] Doxorubicinum Doxorubicinum [INN-Latin] EINECS 245-495-6 FI 106 Farmablastina (hydrochloride salt) HMS2089H06 HSDB 3070 Hydroxydaunomycin hydrochlor ide (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin Hydroxydaunorubicin hydrochloride (hydrochloride salt) JT9100000 LMPK13050001 LS-1029 LS-165655 MLS000759533 Myocet NCI-C01514 NChemBio.2007.10-comp13 NDC 38242-874 NIOSH/JT9100000 NSC 123127 Prestwick0_000438 Prestwick1_000438 Prestwick2_000438 Prestwick3_000438 Probes1_000151 Probes2_000129 RDF Rubex Resmycin Rubex Rubex (hydrochloride salt) SMP1_000106 SPBio_002395 TLC D-99 ThermoDox Triferric doxorubicin UNII-80168379AG adiblastine (hydrochloride salt) adr iablatina (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) adriblatina (hydrochloride salt) doxorubicin nchembio809-comp5 |
| | 19 | | Etoposide | approved | Phase 3, Phase 1, Phase 2 | 1269 | 33419-42-0 | 36462 | (-)-Etoposide 121471-01-0 136598-18-0 201594-04-9 33419-42-0 35317-32-9 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside 51854-34-3 76576-58-4 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one AB00438905 AC1L1FN8 AC1L1VT3 AC1L6246 AC1NR4OG AC1O4WGG AC1O7M1N AC1Q47JJ Ambap33419-42-0 BPBio1_000673 BRD-K37798499-001-02-5 BSPBio_000611 Bio1_000489 Bio1_000978 Bio1_001467 C01576 CCRIS 2392 CHEBI:4911 CHEBI:588795 CHEMBL44657 CID11758093 CID284997 CID3310 CID36462 CID5284558 CID6419930 CID6610299 CPD000112002 D00125 DB00773 DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE, Demethyl Epipodophyllotoxin Ethylidine Glucoside Demethyl-epiodophyllotoxin ethylidene glucoside Demethylepipodophyllotoxin-beta-D-ethylideneglucoside E0675 E1383_SIGMA EINECS 251-509-1 EPE EPEG ETOP Epipodophyllotoxin Epipodophyllotoxin VP-16213 Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside) Eposide Eposin | Eposin, Vepesid, VP-16, Toposar, Etoposide Etopol Etopophos Etopophos (phosphate salt) Etoposid Etoposide Etoposide (JP15/USP/INN) Etoposide (VP16) Etoposide [USAN:INN:BAN:JAN] Etoposido Etoposido [INN-Spanish] Etoposidum Etoposidum [INN-Latin] Etosid HMS1569O13 HMS2052N05 HMS2089F14 HSDB 6517 I06-0248 KBioSS_002410 LS-1214 Lastet MLS000049957 MLS001074951 MLS001424283 MLS002153463 MLS002207239 MLS002222184 MolPort-003-983-431 MolPort-004-905-001 MolPort-004-955-161 NCGC00025056-02 NChemBio.2007.10-comp19 NK 171 NSC 141540 NSC-141540 NSC141540 Prestwick0_000396 Prestwick1_000396 Prestwick2_000396 Prestwick3_000396 Prestwick_211 S1225_Selleck SAM001246880 SMR000112002 SPBio_002532 ST056353 Toposar UNII-6PLQ3CP4P3 VP 16 VP 16 (pharmaceutical) VP 16-213 VP 16213 VP-16 VP-16-213 VePESID (TN) VePesid Vepesid Vepesid J Vepeside ZINC03830818 ZINC03938684 Zuyeyidal etoposide nchembio.573-comp8 nchembio873-comp2 trans-Etoposide |
| | 20 | | Mesna | approved | Phase 3, Phase 1, Phase 2 | 263 | 3375-50-6 | 598 | 2-Mercaptoethane 2-Mercaptoethanesulfonate 2-Mercaptoethanesulfonic acid 2-mercaptoethanesulfonic acid 2-mercaptoethanesulphonic acid 2-mercaptoethylsulfonate 2-sulfanylethylsulfonate | CoM Coenzima M Coenzym M Coenzyme M HS-CoM reduced CoM reduced coenzyme M β-mercaptoethanesulfonic acid | |
| | 21 | | Busulfan | approved, investigational | Phase 3, Phase 2, Phase 1 | 545 | 55-98-1 | 2478 | 1, 4-Dimethanesulfonoxybutane 1, 4-Dimethylsulfonoxybutane 1, {4-Bis[methanesulfonoxy]butane} 1,4-BUTANEDIOL DIMETHANESULFONATE 1,4-Bis(methanesulfonoxy)butane 1,4-Bis(methanesulfonyloxy)butane 1,4-Bis[methanesulfonoxy]butane 1,4-Butanedi yl dimethanesulfonate 1,4-Butanediol dimethanesulfonate 1,4-Butanediol dimethanesulphonate 1,4-Butanediol dimethylsulfonate 1,4-Butanediol, dimethanesulfonate 1,4-Butanediol, dimethanesulphonate 1,4-Butanediyl dimethanesulfonate 1,4-Di(methylsulfonoxy)butane 1,4-Dimesyloxybutane 1,4-Dimethane sulfonyl oxybutane 1,4-Dimethanesulfonoxybutane 1,4-Dimethanesulfonoxylbutane 1,4-Dimethanesulfonyloxybutane 1,4-Dimethanesulphonyloxybutane 1,4-Dimethylsulfonoxybutane 1,4-Dimethylsulfonyloxybutane 2041 C. B 2041 C. B. 2041 C.B 2041 C.B. 4-((Methylsulfonyl)oxy)butyl methanesulfonate 4-methylsulfonyloxybutyl methanesulfonate 55-98-1 AC-198 AC1L1DRQ AC1Q4GRQ AI3-25012 AKOS003614975 AN 33501 Ambap55-98-1 B1022 B2635_FLUKA B2635_SIGMA BRN 1791786 BSPBio_001920 BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE) Bisulfex Busilvex Busulfan Busulfan (JP15/USP/INN) Busulfan GlaxoSmithKline Brand Busulfan Orphan Brand Busulfan Wellcome Busulfan Wellcome Brand Busulfan [INN:JAN] Busulfano Busulfano [INN-Spanish] Busulfanum Busulfanum [INN-Latin] Busulfex Busulphan Busulphane Butanedioldimethanesulfonate Buzulfan C.B. 2041 C6H14O6S2 CB 2041 CCRIS 418 CHEBI:28901 CHEMBL820 CID2478 CPD000058613 Citosulfan D002066 D00248 DB01008 DivK1c_000847 EINECS 200-250-2 FT-0083567 G.T. 41 GT 2041 GT 41 Glaxo Wellcome Brand of Busulfan GlaxoSmithKline Brand of Busulfan Glyzophrol HMS1920I07 HMS2091O09 HMS502K09 | HSDB 7605 I09-1371 IDI1_000847 InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3 KBio1_000847 KBio2_000512 KBio2_003080 KBio2_005648 KBio3_001420 KBioGR_000698 KBioSS_000512 LS-1358 Leucosulfan MLS001076666 MYLERAN (TN) Mablin Methanesulfonic Methanesulfonic acid, tetram ethylene ester Methanesulfonic acid, tetramethylene ester Mielevcin Mielosan Mielucin Milecitan Mileran Misulban Mitosan Mitostan MolPort-001-783-406 Myeleukon Myeloleukon Myelosan Myelosanum Mylecytan Myleran Myleran Tablets Myleran tablets Myleran, Busulfex, Busulfan Mylerlan NCGC00090905-01 NCGC00090905-02 NCGC00090905-03 NCGC00090905-04 NCGC00090905-05 NCGC00090905-06 NCGC00090905-07 NCI-C01592 NCI60_041640 NCIMech_000192 NINDS_000847 NSC 750 NSC-750 NSC-750sulphabutin NSC750 Orphan Brand of Busulfan Prestwick_989 S1692_Selleck SAM002554887 SMR000058613 SPBio_000253 SPECTRUM1500152 ST50825921 Spectrum2_000067 Spectrum3_000320 Spectrum4_000259 Spectrum5_000928 Spectrum_000092 Sulfabutin Sulfabutin (VAN) Sulphabutin Tetramethylene Dimethane Sulfonate Tetramethylene bis(methanesulfonate) Tetramethylene bis[methanesulfonate] Tetramethylene dimethane sulfonate Tetramethylene {bis[methanesulfonate]} Tetramethylenester Kyseliny Methansulfonove Tetramethylenester kyseliny methansulfonove Tetramethylenester kyseliny methansulfonove [Czech] UNII-G1LN9045DK WLN: WS1&O4OSW1 Wellcome Brand of Busulfan Wellcome, Busulfan X 149 acid, tetramethylene ester alkylating agent: crosslinks guanine residues busulfan butane-1,4-diyl dimethanesulfonate n-Butane-1,3-di(methylsulfonate) |
| | 22 | | Mechlorethamine | approved | Phase 3, Phase 2, Phase 1 | 397 | 51-75-2 | 4033 | .Beta.,.beta.'-Dichlorodiethyl-N-methylamine 1, 5-Dichloro-3-methyl-3-azapentane hydrochloride 126-85-2 (N-oxide) 2,2'-Dichloro-N-me 2,2'-Dichloro-N-methyldiethylamine 2,2'-Dichlorodiethyl-methylamine 2,2'-dichloro-N-methyldiethylamine 2-Chloro-N-(2-chloroethyl)-N-methylethanamine 302-70-5 (N-oxide, hydrochloride) 51-75-2 55-86-7 (HYDROCHLORIDE) AC1L1H9H Antimit BRN 0605323 BSPBio_001947 Bis(2-chloroethyl)methylamine Bis(beta-chloroethyl) methylamine Bis(beta-chloroethyl)methylamine C07115 C5H11Cl2N CCRIS 447 CHEBI:28925 CHEMBL427 CID4033 Carolysine Caryolysin Caryolysine Chloramine (the nitrogen mustard) Chlorethazine Chlormethine Chlormethine (INN) Chlormethine [INN:BAN] Chlormethinum [INN-Latin] Cloramin Clormetina Clormetina [INN-Spanish] D07671 DB00888 Di(2-chloroethyl)methylamine Dichlor amine Dichloren DivK1c_000759 EINECS 200-120-5 ENT-25294 Embechine Embichin HMS1920J15 HMS2091B04 HMS502F21 HN-2 HN2 HSDB 5083 I14-8708 IBS-L0033631 IDI1_000759 KBio1_000759 KBio2_001369 KBio2_003937 KBio2_006505 KBio3_001447 | KBioGR_001448 KBioSS_001369 LS-7559 MBA Me chloroethamine Mebichloramine Mechlorethamine Mechlorethanamine Mechloroethamine Mecloretamina Mecloretamina [Italian] Methylbis(2-chloroethyl)amine Methylbis(beta-chloroethyl)amine Methyldi(2-chloroethyl)amine Mitoxine (*Hydrochloride*) MolPort-001-785-592 Mustargen Mustine Mustine note Mutagen N,N-Bis(2-chloroethyl)-N-methylamine N,N-Bis(2-chloroethyl)methylamine N,N-Di(chloroethyl)methylamine N-Lost N-Methyl lost N-Methyl-2,2'-dichlorodiethylamine N-Methyl-bis(2-chloroethyl)amine N-Methyl-bis(beta-chloroethyl)amine N-Methyl-bis-chloraethylamin N-Methyl-bis-chloraethylamin [German] N-Methyl-lost N-Methyl-lost [German] N-methyl-bis(2-chloroethyl)amine NCGC00091835-02 NCGC00091835-03 NCGC00091835-04 NCGC00091835-05 NCI60_041682 NINDS_000759 NSC762 Nitol (*Hydrochloride*) Nitrogen mustard Nitrogen mustard (HN-2) Nitrogranulogen SPBio_000496 SPECTRUM1500375 Spectrum2_000448 Spectrum3_000484 Spectrum4_000924 Spectrum5_001702 Spectrum_000889 Stickstofflost (*Hydrochloride*) Stickstofflost (ebewe) T 1024 T-1024 TL 146 UNII-50D9XSG0VR beta,Beta'-dichlorodiethyl-N-methylamine beta,beta'-Dichlorodiethyl-N-methylamine mechlorethamine thyldiethylamine β,β'-dichlorodiethyl-N-methylamine |
| | 23 | | Vincristine | approved, investigational | Phase 3, Phase 2, Phase 1 | 922 | 2068-78-2, 57-22-7 | 5978 | 22-Oxovincaleukoblastin 22-Oxovincaleukoblastine 28379-27-3 57-22-7 AC1L1LJC C07204 C46H56N4O10 CCRIS 5763 CHEBI:28445 CID5978 D08679 DB00541 EINECS 200-318-1 HMS2090E19 HSDB 3199 Indole alkaloid LCR LS-228 Leurocristine Lilly 37231 (1:1 sulfate salt) Liposomal Vincristine Marqibo NCGC00163700-01 NCI-C04864 NCI60_026703 NSC-67574 Onco TCS | Oncovin Oncovin (1:1 sulfate salt) Oncovine Tecnocris Tecnocris (TN) UNII-5J49Q6B70F VCR VIN Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine Vincasar Vincasar (1:1 sulfate salt) Vincasar PFS Vincrex Vincrex (1:1 sulfate salt) Vincristin Vincristina Vincristina [DCIT] Vincristine (INN) Vincristine Sulfate Vincristine Sulfate PFS Vincristine [INN:BAN] Vincristinum Vincristinum [INN-Latin] Vincrstine Vincrystine Vinkristin Z-D-Val-Lys(Z)-OH vincristine | |
| | 24 | | Lenograstim | approved | Phase 3, Phase 2, Phase 1 | 1220 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 25 | | Carboplatin | approved | Phase 3, Phase 1, Phase 2 | 2050 | 41575-94-4 | 10339178, 498142, 38904 | (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum /h1-3H2,(H,7,8)(H,9,10) /q 1,1-Cyclobutanedicarboxylate diammine platinum (II) 1,1-Cyclobutanedicarboxylate diammine platinum(II) 2*-1 2*1H2 41575-94-4 70903-55-8 AC-1457 AC1L8I6U Ambap41575-94-4 BSPBio_003145 C 2538 C2043 C2538_SIGMA C6H10N2O4Pt CBDCA CCRIS 3404 CHEBI:31355 CHEMBL1351 CHEMBL288376 CID10339178 CID2567 CID38904 CID426756 CID498142 CID5352133 CID6398587 CID6603770 Carbopaltin Carboplatin Carboplatin (JAN/USP/INN) Carboplatin (USAN) Carboplatin [USAN:INN:BAN:JAN] Carboplatine Carboplatine [French] Carboplatino Carboplatino [Spanish] Carboplatinum Carboplatinum [Latin] Cbdca Cyclobutane-1,1-dicarboxylate D01363 DB00958 Diammine(1,1-cyclobutanedicarboxylato)platinum (II) Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum Diammine-1,1-cyclobutane dicarboxylate platinum II DivK1c_000892 EINECS 255-446-0 EU-0100230 Ercar HMS1921J16 HMS2090M05 HMS2092B22 HMS502M14 HSDB 6957 I14-2390 IDI1_000892 IUPAC: Azane InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6 | JM 8 JM-8 KBio1_000892 KBio2_002009 KBio2_004577 KBio2_007145 KBio3_002645 KBioGR_000713 KBioSS_002009 LS-117689 Lopac-C-2538 Lopac0_000230 MolPort-003-665-501 MolPort-003-845-609 NCGC00015223-01 NCGC00093695-01 NCGC00094961-01 NCGC00094961-02 NCGC00094961-03 NCGC00162099-01 NCGC00162099-02 NCGC00167800-01 NCGC00178242-01 NINDS_000892 NSC 201345 NSC 241240 NSC-241240 NSC201345 NSC241240 Paraplatin Paraplatin (TN) Paraplatin, Carboplatin Paraplatin-AQ Platinum(+2) Cation Platinum(II), (1, 1-cyclobutanedicar Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2) Platinum, {diammine[1,1-cyclobut S1215_Selleck SPBio_000716 SPECTRUM1502106 Spectrum2_000898 Spectrum3_001503 Spectrum4_000337 Spectrum5_001094 Spectrum_001529 UNII-BG3F62OND5 azanide carboplatin cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii) cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II) cis-Diammine(1,1-cyclobutanedicarboxylato) platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diammine(cyclobutanedicarboxylato)platinum II cyclobutane-1,1-dicarboxylic acid diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum nchembio.573-comp10 nchembio773-comp2 nchembio873-comp3 platinum(2+) |
| | 26 | | Fentanyl | approved, illicit, investigational, vet_approved | Phase 3 | 821 | 437-38-7 | 3345 | 1-Phenethyl-4-(N-phenylpropionamido)piperidine 1-Phenethyl-4-N-propionylanilinopiperidine 1-phenethyl-4-N-propionylanilinopiperidine 437-38-7 5-22-08-00049 (Beilstein Handbook Reference) 80832-90-2 990-73-8 (citrate) AC1L1FQ2 Actiq BIDD:GT0555 BRN 0494484 CHEBI:119915 CHEMBL596 CID3345 D00320 DB00813 Duragesic Duragesic (TN) Duragesic-100 Duragesic-12 Duragesic-25 Duragesic-50 Duragesic-75 Durogesic EINECS 207-113-6 Fentanest Fentanil Fentanil [DCIT] Fentanila Fentanila [INN-Spanish] Fentanilo Fentanyl Fentanyl (JAN/USAN/INN) Fentanyl CII Fentanyl [INN:BAN] Fentanyl citrate Fentanyl-100 Fentanyl-12 Fentanyl-25 | Fentanyl-50 Fentanyl-75 Fentanylum Fentanylum [INN-Latin] HSDB 3329 IONSYS JNS020QD L001275 LS-124439 Matrifen MolPort-003-847-369 N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-Phenethyl-4-piperidyl)propionanilide N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-phenethyl-4-piperidyl)propionanilide N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide N-Phenethyl-4-(N-propionylanilino)piperidine N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenethyl-4-(N-propionylanilino)piperidine N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide NCGC00168252-01 Nasalfent Oprea1_152073 Oprea1_207148 PDSP1_000860 PDSP2_000846 Pentanyl Phentanyl Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI) R 4263 Rapinyl Sentonil Sublimase Sublimaze UNII-UF599785JZ fentanyl | |
| | 27 | | Epirubicin | approved | Phase 3, Phase 2 | 394 | 56420-45-2 | 41867 | (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione 4'-Epi-DXR 4'-Epiadriamycin 4'-Epidoxorubicin 4'-epi-DX 4'-epi-Doxorubicin 4'-epidoxorubicin 4-Epidoxorubicin 56390-09-1 56390-09-1 (hydrochloride) 56420-45-2 57918-25-9 AC1L26NP AC1Q6JIV BRN 1445813 C11230 C27H29NO11 CCRIS 2261 CHEBI:47898 CHEMBL417 CID41867 D07901 DB00445 Ellence Epi-DX Epi-Dx Epiadriamycin Epidoxorubicin Epirubicin | Epirubicin (INN) Epirubicin [INN:BAN] Epirubicina Epirubicina [INN-Spanish] Epirubicina [Spanish] Epirubicine Epirubicine [French] Epirubicine [INN-French] Epirubicinum Epirubicinum [INN-Latin] Epirubicinum [Latin] Farmorubicin (TN) HSDB 6962 IMI 28 LS-187190 LS-93992 MLS000759412 NChemBio.2007.10-comp15 NSC 256942 NSC-256942 NSC256942 Pharmorubicin Pfs Pidorubicin Pidorubicina Pidorubicina [INN-Spanish] Pidorubicine Pidorubicine [INN-French] Pidorubicinum Pidorubicinum [INN-Latin] Ridorubicin SMR000466308 Triferric doxorubicin UNII-3Z8479ZZ5X WP 697 | |
| | 28 | | Histamine | approved, investigational | Phase 3 | 1050 | 75614-87-8, 51-45-6 | 774 | .beta.-Imidazolyl-4-ethylamine 1H-Imidazole-4-ethanamine 1H-Imidazole-5-ethanamine 1avn 1qft 2-(1H-Imidazol-4-yl)ethanamine 2-(1H-Imidazol-4-yl)ethylamine 2-(1H-Imidazol-5-yl)ethanamine 2-(1H-Imidazol-5-yl)ethylamine 2-(1H-imidazol-4-yl)ethan-1-amine 2-(1H-imidazol-5-yl)ethanamine 2-(3H-Imidazol-4-yl)-ethylamine 2-(4-Imidazolyl)ethanamine 2-(4-Imidazolyl)ethylamine 2-(4-imidazolyl)ethylamine 2-Imidazol-4-yl-Ethylamine 2-Imidazol-4-ylethylamine 2-[4-Imidazolyl]ethylamine 4-(2-Aminoethyl)-1H-imidazole 4-(2-Aminoethyl)imidazole 4-Imidazoleethylamine 4-imidazoleethylamine 5-Imidazoleethylamine 5-imidazoleethylamine 51-45-6 53290_FLUKA 64422-25-9 924364-91-0 AC-13185 AC1L19ZT AC1Q54BV AC1Q54BW AKOS000274386 ALBB-005968 BCBcMAP01_000250 BSPBio_001117 BSPBio_002124 Bio1_000487 Bio1_000976 Bio1_001465 Bio2_000389 Bio2_000869 C00388 CCRIS 6535 CHEBI:18295 CHEMBL90 CID774 D08040 DivK1c_000308 EINECS 200-100-6 Eramin Ergamine Ergotidine F411C768-A159-4FC0-A195-291A08BB03AA Free histamine H7125_SIGMA HMS1362G19 HMS1792G19 HMS1990G19 HSDB 3338 HSM Histamine Histamine (DCF) Histamine Base Histamine [USAN] Histamine, Free Base Histaminum | Histaminum (TN) IDI1_000308 IDI1_002144 Imidazole-4-ethylamine Istamina Istamina [Italian] KBio1_000308 KBio2_000457 KBio2_001325 KBio2_003025 KBio2_003893 KBio2_005593 KBio2_006461 KBio3_000853 KBio3_000854 KBio3_001344 KBioGR_000457 KBioGR_001580 KBioSS_000457 KBioSS_001325 L-Histamin base L-Histamine L-histamine L000292 LS-75835 Lopac-H-7250 Lopac0_000595 MLS000069447 MolPort-001-785-597 MolPort-002-042-264 NCGC00015513-01 NCGC00015513-08 NCGC00093371-02 NCGC00093371-03 NCGC00093371-04 NCGC00093371-05 NINDS_000308 NSC 33792 NSC33792 SDCCGMLS-0066601.P001 SMP1_000151 SMR000059091 SPBio_000729 ST073926 STK346752 STOCK5S-55669 Spectrum2_000665 Spectrum3_000452 Spectrum4_000960 Spectrum5_000796 Spectrum_000845 Theramine UNII-820484N8I3 WLN: T5M CNJ D2Z ZERO/004089 [3H]histamine b-Imidazolyl-4-ethylamine beta-Aminoethylglyoxaline beta-Aminoethylimidazole beta-Aminothethylglyoxaline beta-Imidazolyl-4-ethylamine beta-aminoethylglyoxaline beta-aminoethylimidazole beta-aminothethylglyoxaline bmse000744 histamine nchembio.87-comp54 nchembio714-comp1 | |
| | 29 | | Topotecan | approved, investigational | Phase 3, Phase 2, Phase 1 | 349 | 119413-54-6, 123948-87-8 | 60700 | (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione 123948-87-8 9-Dimethylaminomethyl-10-hydroxycamptothecin 9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin AC-11592 AC1L1TQZ AC1Q6APZ BSPBio_002348 C11158 C23H23N3O5 CCRIS 8163 CHEBI:107501 CHEBI:46035 CHEMBL84 CID60700 D08618 DB01030 HMS2090B20 HSCI1_000228 Hycamptamine Hycamptin Hycamtamine Hycamtin Hycamtin (TN) LS-127395 | MLS000759456 NCGC00178695-01 NCI60_004771 NCIStruc1_001659 NCIStruc2_001796 NChemBio.2007.10-comp24 NSC609699 SK&F-104864-A SKF 104864 SKF-104864-A SKF-S 104864 SMP2_000312 SMP2_000327 SMR000466344 TOPO TOPOTECAN, HYCAMTIN TPT TTC Topotecan (BAN) Topotecan Hcl Topotecan Hydrochloride Topotecan Lactone Topotecan Monohydrochloride, (S)-Isomer Topotecan [INN:BAN] Topotecan lactone Topotecane Topotecane [INN-French] Topotecanum Topotecanum [INN-Latin] UNII-7M7YKX2N15 topotecan |
| | 30 | | Zoledronic acid | approved | Phase 3, Phase 1 | 294 | 118072-93-8 | 68740 | (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid 118072-93-8 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid AC-1092 AC1L2ACJ AC1Q6RN3 AKOS005145739 Aclasta Anhydrous Zoledronic Acid BIDD:GT0292 BIDD:PXR0134 Bio-0112 Bisphosphonate 3 C088658 CGP 42'446 CGP 42446 CGP 42446A CGP-42'446 CGP-42446 CHEBI:46557 CHEMBL924 CID68740 D08689 DB00399 | FT-0082657 HMS2089O09 I06-0710 KS-1132 LS-181815 MolPort-002-885-874 MolPort-003-850-890 NCGC00159521-02 NCGC00159521-03 NSC721517 Novartis brand of zoledronic acid Reclast Reclast (TN) S00092 S1314_Selleck UNII-70HZ18PH24 ZOL Zol Zoledronate Zoledronic Acid Anhydrous Zoledronic Acid, Anhydrous Zoledronic acid Zoledronic acid (INN) Zoledronic acid [USAN:INN] Zometa Zometa (Novartis) Zometa (TN) Zometa Concentrate Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) | |
| | 31 | | Idarubicin | approved | Phase 3 | 214 | 58957-92-9 | 42890 | (1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione 4-DMD 4-Demethoxydaunomycin 4-Demethoxydaunorubicin 4-Desmethoxydaunorubicin 57852-57-0 57852-57-0 (HYDROCHLORIDE) 58957-92-9 AC1L28SA AC1Q6JJ4 BRD-K69650333-001-01-1 C26H27NO9 CCRIS 5083 CHEBI:42068 CHEMBL1117 CID42890 D08062 DB01177 DM5 DMDR EU-0100600 HMS2089D05 I 1656 I06-1097 I1656_SIGMA IDARUBICIN | IMI 30 IMI-30 Idamycin Idamycin PFS Idarubicin (INN) Idarubicin Aglycone Idarubicin HCl PFS Idarubicin Hcl Idarubicin Hcl Pfs Idarubicin Hydrochloride Idarubicin [INN:BAN] Idarubicina Idarubicina [INN-Spanish] Idarubicine Idarubicine [INN-French] Idarubicinum Idarubicinum [INN-Latin] KBioSS_002388 LS-94015 Lopac0_000600 MLS000759470 NCGC00093976-01 NCGC00093976-02 NCGC00093976-03 NCGC00093976-04 NSC-256439 NSC256439 SMR000466355 UNII-ZRP63D75JW Zavedos Zavedos (TN) idarubicin hydrochloride |
| | 32 | | Cyproheptadine | approved | Phase 3 | 20 | 129-03-3 | 2913 | 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine 129-03-3 4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine 4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine 4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine 41354-29-4 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene 5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene 5-20-08-00500 (Beilstein Handbook Reference) AC1L1ER8 AKOS004119847 Axoprol BIDD:GT0324 BPBio1_000096 BPBio1_000155 BRD-K28143534-001-01-4 BRD-K28143534-003-03-6 BRN 1685976 BSPBio_000086 Biomol-NT_000131 C06935 CAS-969-33-5 CCRIS 5232 CHEBI:4046 CHEMBL516 CID2913 CYPROHEPTADINE Ciproheptadina Ciproheptadina [INN-Spanish] Ciprovit Ciprovit (TN) Cypoheptadine Cyproheptadiene Cyproheptadin Cyproheptadine | Cyproheptadine (INN) Cyproheptadine Hcl Cyproheptadine [INN:BAN] Cyproheptadinum Cyproheptadinum [INN-Latin] D07765 DB00434 Dibenzosuberonone/Cyproheptadine Dihexazin Dronactin EINECS 204-928-9 Eiproheptadine Glutodina HMS2090P20 HSDB 3048 L001016 LS-114933 Lopac-C-6022 Lopac0_000246 MK 141 MolPort-002-507-777 NCGC00015252-01 NCGC00015252-02 NCGC00015252-03 NCGC00015252-09 NCGC00024293-02 NCGC00024293-04 NCGC00024293-05 Oprea1_498140 PDSP1_001229 PDSP2_001213 Periactin Periactine Periactinol Prestwick0_000103 Prestwick1_000103 Prestwick2_000103 Prestwick3_000103 SPBio_002025 STK802098 Tocris-0996 UNII-2YHB6175DO Viternum nchembio.559-comp10 |
| | 33 | | Doxil | Approved June 1999 | Phase 3, Phase 2, Phase 1 | 1751 | | 31703 | | Evacet LipoDox Pegylated Liposomal Doxorubicin Hydrochloride liposomal doxorubicin |
| | 34 | | Peripheral Nervous System Agents | | Phase 3, Phase 2, Phase 1 | 23689 | | | | 35 | | Antineoplastic Agents, Hormonal | | Phase 2, Phase 3, Phase 1 | 5592 | | | | 36 | | Liver Extracts | | Phase 3, Phase 2, Phase 1 | 4067 | | | | 37 | | Protective Agents | | Phase 3, Phase 2, Phase 1 | 7443 | | | | 38 | | Gastrointestinal Agents | | Phase 3, Phase 2, Phase 1 | 8402 | | | | 39 | | Isophosphamide mustard | | Phase 3, Phase 2, Phase 1 | 400 | | | | 40 | | Antineoplastic Agents, Alkylating | | Phase 3, Phase 1, Phase 2 | 4603 | | | | 41 | | Antineoplastic Agents, Phytogenic | | Phase 3, Phase 2, Phase 1 | 5602 | | | | 42 | | Antirheumatic Agents | | Phase 3, Phase 1, Phase 2 | 10956 | | | | 43 | | Antimitotic Agents | | Phase 3, Phase 2, Phase 1 | 5657 | | | | 44 | | Antibiotics, Antitubercular | | Phase 3, Phase 2, Phase 1 | 7180 | | | | 45 | | Alkylating Agents | | Phase 3, Phase 2, Phase 1 | 4827 | | | | 46 | | Anti-Bacterial Agents | | Phase 3, Phase 2, Phase 1 | 11226 | | | | 47 | | Etoposide phosphate | | Phase 3, Phase 1, Phase 2 | 1269 | | | | 48 | | Cobalt | | Phase 3, Phase 2 | 167 | 7440-48-4 | 104729 | | Cobalt-59 Cobatope-57 Kobalt Super cobalt |
| | 49 | | Adjuvants, Immunologic | | Phase 3, Phase 2, Phase 1 | 2554 | | | | 50 | | Nucleic Acid Synthesis Inhibitors | | Phase 3, Phase 2, Phase 1 | 4962 | | |
Interventional clinical trials: (show top 50)
(show all 255)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Dolutegravir and Darunavir Evaluation in Adults Failing Therapy | Not yet recruiting | NCT03017872 | Phase 4 | | 2 | Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma | Unknown status | NCT00002516 | Phase 3 | | 3 | Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma | Unknown status | NCT00020566 | Phase 3 | | 4 | Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor | Completed | NCT00006734 | Phase 3 | | 5 | Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain | Completed | NCT00538850 | Phase 3 | | 6 | Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant | Completed | NCT00305851 | Phase 3 | | 7 | Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma | Completed | NCT00002898 | Phase 3 | | 8 | Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma | Recruiting | NCT02063022 | Phase 3 | | 9 | Study in Localized and Disseminated Ewing Sarcoma | Recruiting | NCT00987636 | Phase 3 | | 10 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | Recruiting | NCT02306161 | Phase 3 | | 11 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer | Recruiting | NCT02856048 | Phase 2, Phase 3 | | 12 | Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma | Recruiting | NCT00876031 | Phase 3 | | 13 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | Active, not recruiting | NCT01231906 | Phase 3 | | 14 | Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer | Terminated | NCT01132547 | Phase 3 | | 15 | Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients | Withdrawn | NCT01734863 | Phase 3 | | 16 | Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma | Withdrawn | NCT00334867 | Phase 3 | | 17 | Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas | Unknown status | NCT00998361 | Phase 2 | | 18 | Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse | Unknown status | NCT00180947 | Phase 2 | | 19 | Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors | Unknown status | NCT00003515 | Phase 2 | | 20 | Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | Unknown status | NCT00179816 | Phase 1, Phase 2 | | 21 | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | NCT00084695 | Phase 2 | | 22 | Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy | Completed | NCT01222767 | Phase 2 | | 23 | Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor | Completed | NCT00062205 | Phase 2 | | 24 | Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors | Completed | NCT00560235 | Phase 1, Phase 2 | | 25 | Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors | Completed | NCT00070109 | Phase 2 | | 26 | Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors | Completed | NCT00061893 | Phase 2 | | 27 | Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma | Completed | NCT01583543 | Phase 2 | | 28 | New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma | Completed | NCT00001335 | Phase 2 | | 29 | Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma | Completed | NCT02546544 | Phase 2 | | 30 | Aerosol L9-NC and Temozolomide in Ewing's Sarcoma | Completed | NCT00492141 | Phase 1, Phase 2 | | 31 | Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma | Completed | NCT00276692 | Phase 2 | | 32 | Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma | Completed | NCT00516295 | Phase 2 | | 33 | Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma | Completed | NCT00470275 | Phase 2 | | 34 | Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors | Completed | NCT00357396 | Phase 2 | | 35 | Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor | Completed | NCT00002643 | Phase 2 | | 36 | Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma | Completed | NCT00073983 | Phase 2 | | 37 | Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone | Completed | NCT00006234 | Phase 1, Phase 2 | | 38 | Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma | Completed | NCT00003667 | Phase 2 | | 39 | Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor | Completed | NCT00055952 | Phase 2 | | 40 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer | Completed | NCT00002466 | Phase 2 | | 41 | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma | Completed | NCT00668148 | Phase 2 | | 42 | A Study of R1507 in Participants With Recurrent or Refractory Sarcoma | Completed | NCT00642941 | Phase 2 | | 43 | QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors | Completed | NCT00563680 | Phase 2 | | 44 | A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas | Completed | NCT00001566 | Phase 2 | | 45 | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas | Completed | NCT00001564 | Phase 2 | | 46 | Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas | Completed | NCT00165139 | Phase 2 | | 47 | A Study of Pemetrexed in Children With Recurrent Cancer | Completed | NCT00520936 | Phase 2 | | 48 | Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure | Completed | NCT01136499 | Phase 2 | | 49 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | Completed | NCT01288573 | Phase 1, Phase 2 | | 50 | Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma | Completed | NCT00006102 | Phase 2 |
|
